Evidence map›Paper›PMID 29649529›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2018

Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering.

Qingqing Yao, Yangxi Liu, Balaranjan Selvaratnam, Ranjit T Koodali, Hongli Sun

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 142 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Qingqing YaoDepartment of Biomedical Engineering, University of South Dakota, BioSNTR, Sioux Falls, SD 57107, USA; School of Ophthalmology and Optometry, Wenzhou Medical University, 270 Xueyuan Xi Road, Wenzhou, Zhejiang 325027, China; Institute of Advanced Materials for Nano-Bio Applications, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.
Yangxi LiuDepartment of Biomedical Engineering, University of South Dakota, BioSNTR, Sioux Falls, SD 57107, USA.
Balaranjan SelvaratnamDepartment of Chemistry, University of South Dakota, 414 E. Clark Street, Vermillion 57069, SD, USA.
Ranjit T KoodaliDepartment of Chemistry, University of South Dakota, 414 E. Clark Street, Vermillion 57069, SD, USA.
Hongli SunDepartment of Biomedical Engineering, University of South Dakota, BioSNTR, Sioux Falls, SD 57107, USA. Electronic address: hongli.sun@usd.edu.
University of South Dakota · US

Funding

Yeast 2 HybridP20GM103620 · NIGMS · SANFORD RESEARCH/USD · PI ROUX, KYLE J · 2013 to 2023
$24.2M
The Impact of PD-1 Inhibition on Immune-Response to ChemoradiotherapyP20GM103548 · NIGMS · SANFORD RESEARCH/USD · PI MISKIMINS, W KEITH · 2012 to 2020
$20.8M
Functionalized Nanofibrous Scaffold for Endogenous Bone RegenerationR03DE027491 · NIDCR · UNIVERSITY OF SOUTH DAKOTA · PI SUN, HONGLI · 2018 to 2019
$304k
NIDCR NIH HHS R03 DE027491NIGMS NIH HHS P20 GM103548NIGMS NIH HHS P20 GM103620
6 · The paper itself

Abstract

Controlled delivery systems play a critical role in the success of bone morphogenetic proteins (i.e., BMP2 and BMP7) for challenged bone repair. Instead of single-drug release that is currently and commonly prevalent, dual-drug delivery strategies are highly desired to achieve effective bone regeneration because natural bone repair process is driven by multiple factors. Particularly, angiogenesis is essential for osteogenesis and requires more than just one factor (e.g., Vascular Endothelial Growth Factor, VEGF). Therefore, we developed a novel mesoporous silicate nanoparticles (MSNs) incorporated-3D nanofibrous gelatin (GF) scaffold for dual-delivery of BMP2 and deferoxamine (DFO). DFO is a hypoxia-mimetic drug that can activate hypoxia-inducible factor-1 alpha (HIF-1α), and trigger subsequent angiogenesis. Sustained BMP2 release system was achieved through encapsulation into large-pored MSNs, while the relative short-term release of DFO was engineered through covalent conjugation with chitosan to reduce its cytotoxicity and elongate its half-life. Both MSNs and DFO were incorporated onto a porous 3D GF scaffold to serve as a biomimetic osteogenic microenvironment. Our data indicated that DFO and BMP2 were released from a scaffold at different release rates (10 vs 28 days) yet maintained their angiogenic and osteogenic ability, respectively. Importantly, our data indicated that the released DFO significantly improved BMP2-induced osteogenic differentiation where the dose/duration was important for its effects in both mouse and human stem cell models. Thus, we developed a novel and tunable MSNs/GF 3D scaffold-mediated dual-drug delivery system and studied the potential application of the both FDA-approved DFO and BMP2 for bone tissue engineering.

Indexed as

Drug Delivery SystemsAnimalsBone and BonesBone Morphogenetic Protein 2Cell DifferentiationChitosanDeferoxamineDrug LiberationGelatinHumansMesenchymal Stem CellsMiceNanofibersNanoparticlesOsteogenesisPorosityBone Morphogenetic Protein 2ChitosanDeferoxamineGelatinSilicatesAngiogenesisDeferoxamineDual release systemMesoporous silicate nanoparticlesNanofibrous scaffoldOsteogenesis

Identifiers

PMID29649529
PMCPMC5972066
OpenAlexW2797396730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.